
    
      The primary safety endpoint of the study is freedom from Major Adverse Events (MAE), a
      composite endpoint consisting of death, stroke, paraplegia, myocardial infarction,
      respiratory failure, renal failure, bowel ischemia and blood loss â‰¥ 1000 mL.
    
  